learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 26 resultslearn GT20029
research compound made to degrade androgen receptors in scalp
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
learn Overview
Research
5 / 1000+ resultsresearch Alopecia Areata Clinical Trial Enrollment and Retention Outcome Factors Among Underrepresented Ethnic and Racial Groups: A Cross-Sectional Study
research Budesonide for Maintenance of Remission in Crohn's Disease
Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
research Dermatology Resident Comfort Level Treating Hair Conditions Related to Patients with Skin of Color
Dermatology residents need better training to treat hair conditions in patients with skin of color.
research Use of Silver in the Prevention and Treatment of Infections: A Review
Silver can help prevent and treat infections but its effectiveness varies and should be weighed against costs and side effects.
research The BJUI's Clinical Trials Initiative
The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
Community Join
5 / 820 resultscommunity Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
community Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia
Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.